Diabetes mellitus in acute myocardial infarction patients receiving thrombolysis was associated with lower late infarct-related artery patency compared to nondiabetics (28.9% vs 41.3%, p<0.001).
Observational
Does coexistent diabetes mellitus adversely affect the outcomes of thrombolytic therapy in patients with acute myocardial infarction?
Coexistent diabetes mellitus is associated with poorer late angiographic patency and worse left ventricular function following thrombolytic therapy for acute myocardial infarction.
Absolute Event Rate: 28.9% vs 41.3%
p-value: p=<0.001
This study was performed to evaluate whether coexistent diabetes mellitus has any adverse effect on the outcomes of thrombolytic therapy in patients with acute myocardial infarction. Although the early reperfusion rates were similar between the two groups of patients who had acute myocardial infarction with and without diabetes mellitus (42% vs 45.4%, p > 0.05), the results of late angiographic examination showed a significantly lower rate of patency in infarct-related coronary artery (defined as TIMI 3 flow) in diabetics compared to nondiabetics (28.9% vs 41.3%, p < 0.001). The global left ventricular function was also poorer in diabetics (left ventricular wall motion score was 18.6 +/- 7.3 in diabetics and 14.1 +/- 4.6 in nondiabetics, p < 0.01).
Tıkız et al. (Tue,) conducted a observational in Acute Myocardial Infarction. Diabetes mellitus (exposure) vs. No diabetes mellitus was evaluated on Late angiographic patency in infarct-related coronary artery (TIMI 3 flow) (p=<0.001). Diabetes mellitus in acute myocardial infarction patients receiving thrombolysis was associated with lower late infarct-related artery patency compared to nondiabetics (28.9% vs 41.3%, p<0.001).